# Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria

> **NCT00481676** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 49 (actual)

## Conditions studied

- Chronic Urticaria

## Interventions

- **DRUG:** Omalizumab 75-375 mg
- **DRUG:** Placebo to omalizumab
- **DRUG:** Loratadine
- **DRUG:** Clemastine

## Key facts

- **NCT ID:** NCT00481676
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2011-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00481676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00481676, "Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00481676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*